Opc,

I think Arditi had much to do with that.

Also, I am encouraged by the consistency and patience the company is showing with the screening of the prospective study patients. It appears MannKind is not going to allow bad clinical patients to screw these trials up.

Despite the fact the recruitment is taking longer than expected, we have much to look forward to with positive trial results. Right after trials end we can look forward to proceeding immediately into European approvals since their requirements will be satisfied with the current trials.

You have mentioned any partnership agreement will probably not involve much up front money from a partner. If a partner decides to buy in I would be surprised if the cash part of the deal was not substantial. MNKD has to take care of the 2013 bonds plus keep the cash burn satisfied heading into a launch.

Nothing a $200,000,000 sale to a small country wouldn't care of....